Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering speci... Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Show more
Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase...
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -1.3671875 | 10.24 | 10.31 | 9.25 | 3183145 | 9.62466673 | CS |
4 | -1.73 | -14.6238377008 | 11.83 | 13.34 | 9.25 | 3092769 | 10.86130844 | CS |
12 | -4.7 | -31.7567567568 | 14.8 | 17.83 | 9.25 | 2753183 | 13.23186077 | CS |
26 | -14.93 | -59.6484218937 | 25.03 | 27.42 | 9.25 | 2168659 | 16.41279859 | CS |
52 | -15.68 | -60.8223429015 | 25.78 | 34.87 | 9.25 | 1873836 | 20.20545894 | CS |
156 | -68.89 | -87.2135713381 | 78.99 | 104.87 | 9.25 | 1394305 | 34.88767181 | CS |
260 | -4.27 | -29.7146833681 | 14.37 | 202.73 | 9.18 | 1312865 | 49.82913224 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales